PR positive

About

Biomarker Type: Protein expression

Present: True

Marker: Progesterone receptor (PR)

Unit: status

Equality: =

Value: Positive


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (2) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 somatic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, PR positive Invasive Breast Carcinoma Fulvestrant
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (2) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (1) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
EMA (1) FDA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (1) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan
EMA (1) HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan